Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Federal Reserve Faces Subpoena Delay Amid Investigation Into Chair Jerome Powell 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
JPMorgan Lifts Gold Price Forecast to $6,300 by End-2026 on Strong Central Bank and Investor Demand 
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
U.S. Stock Futures Rise as Investors Eye Big Tech Earnings and AI Momentum 
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Minnesota Judge Rejects Bid to Halt Trump Immigration Enforcement in Minneapolis 
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants 
Fifty-seven lawsuits alleging that hair relaxer products sold by L'Oreal USA Inc and two India-based firms cause cancer and other health problems will be consolidated before US District Judge Mary Rowland in Chicago,
The Chicago federal court will streamline discovery efforts and other pretrial issues for the cases, according to the order.
The lawsuits, which have been filed in federal courts across the country, alleged that the companies knew about the dangerous chemicals in their products but marketed and sold them anyway.
The cases name the US subsidiary of L'Oreal SA and subsidiaries of India-based companies Godrej SON Holdings Inc. and Dabur International Ltd.
Representatives for the companies opposed the centralization of the cases.
L'Oreal said it is confident in the safety of its products and that lawsuits against it have no legal merit.
The claims come in response to a National Institutes of Health research that was published in October and revealed that women who used the products frequently had a greater than doubled risk of developing uterine cancer.
The panel's decision, according to Diandra Debrosse Zimmermann of DiCello Levitt, who filed the initial case after the study's publication, "recognized the clear benefits of centralizing the hair relaxer litigation," and she anticipates that many more companies will do the same in the upcoming weeks.
As the goods are often promoted to women of color, Zimmermann expects hundreds of women may end up suing over them.
